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Nuclear factor-κB decoy attenuates neuronal damage
after global brain ischemia: A future strategy for brain
protection during circulatory arrest
Takayoshi Ueno, MDa
Yoshiki Sawa, MDa
Satoru Kitagawa-Sakakida, MDa
Motonobu Nishimura, MDa
Ryuichi Morishita, MDb
Yasufumi Kaneda, MDb
Eiji Kohmura, MDc
Toshiki Yoshimine, MDc
Hikaru Matsuda, MDa Objectives: Recent studies have reported that cis element decoy oligodeoxynu-
cleotides against nuclear factor-κB block the activation of genes that mediate
ischemic injury. To improve brain protection during circulatory arrest in cardiac
surgery, we evaluated the efficacy of nuclear factor-κB decoy oligodeoxynu-
cleotides in preventing neuronal damage after global brain ischemia.
Methods: Hemagglutinating virus of Japan–liposome complex with fluorescein
isothiocyanate–labeled nuclear factor-κB decoy oligodeoxynucleotides was inject-
ed through the carotid artery during 20 minutes of global brain ischemia in rats to
evaluate the efficacy of transfecting the decoy oligodeoxynucleotides. The messen-
ger RNA levels of several factors related to ischemia-reperfusion injury in the hip-
pocampus were estimated by a real-time polymerase chain reaction method 1 hour
after reperfusion. Neuronal damage was evaluated by terminal deoxynucleotidyl
transferase–mediated deoxyuridine triphosphate nick end labeling staining and by
using immunohistochemical study of microtubule-associated protein 2 in the hip-
pocampus CA-1 region 7 days after ischemia.
Results: Introduction of the nuclear factor-κB decoy oligodeoxynucleotides into rat
brain neurons through the carotid artery during global brain ischemia was marked-
ly successful. The polymerase chain reaction study showed that the transfected
nuclear factor-κB decoy oligodeoxynucleotides effectively inhibited the expression
of tumor necrosis factor α interleukin 1β and intracellular adhesion molecule 1
messenger RNA 1 hour after global brain ischemia. Terminal deoxynucleotidyl
transferase–mediated deoxyuridine triphosphate nick end labeling staining and
microtubule-associated protein 2 immunohistochemistry showed that the transfect-
ed nuclear factor-κB decoy oligodeoxynucleotides significantly attenuated the neu-
ronal damage 7 days after global brain ischemia.
Conclusions: Therapeutic transfection of nuclear factor-κB decoy oligodeoxynu-
cleotides during brain ischemia may be useful for attenuating neuronal damage,
suggesting a strategy for cerebral protection against global ischemia.
In the field of cardiac surgery, circulatory arrest is commonly used as the sup-port technique in patients with aortic aneurysmal changes or in neonates withcomplex congenital anomalies. However, several complications related to cir-culatory arrest are still unresolved, and longer duration of circulatory arrestresults in a higher incidence of neurologic sequelae.1 During circulatory arrest,the whole body, including the brain, is ischemic, and prolonged ischemia leads
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to necrosis of the neurons. Moreover, brain neurons, especial-
ly those in the hippocampus, will die 5 to 7 days after even a
few minutes of ischemia, a phenomenon called delayed neu-
ronal death.2 Even when techniques such as deep hypothermia
are used to protect the brain against ischemic injury, 45 to 60
minutes is the outer limit for maintaining circulatory arrest,
and deep hypothermia is associated with several risks, includ-
ing increased bleeding, blood transfusion, and a decline of
immunity.3 The development of better techniques for brain
protection against both neuronal necrosis and delayed neu-
ronal death resulting from ischemic insult is desired to
improve the morbidity of operations for aortic and congenital
heart disease.
Recent studies have implicated the activation of nuclear
factor-κB (NF-κB), a crucial transcriptional factor, in neuronal
damage after cerebral ischemia.4-6 NF-κB is a transcriptional
activator of many genes whose expression is related to
ischemia-reperfusion injury, such as cytokines (tumor necrosis
factor α [TNF-α] and interleukin 1β [IL-1β])7 and adhesion
molecules (intracellular adhesion molecule 1 [ICAM-1]).8
Furthermore, inhibitors of NF-κB activation, such as aspirin,
seem to block ischemic injury in neurons.9 It has been report-
ed that the transfection of decoy oligodeoxynucleotides
(ODNs) blocks the transcriptional activation of cytokines and
adhesion molecules,10 and we previously reported the efficacy
of transfecting NF-κB decoy ODNs to prevent ischemic reper-
fusion injury in the heart.11,12
On the basis of these findings, we hypothesized that
transfecting NF-κB decoy ODNs into neurons would pre-
vent neuronal damage after global brain ischemia and that
NF-κB decoy ODNs could provide a new cerebroprotective
therapy. The present study was designed to examine
whether transfecting NF-κB decoy ODNs into the brain
through the carotid artery could attenuate the damage to
neurons after global brain ischemia in a rat model. Our goal
is to develop a new cerebroprotective agent for use during
global brain ischemia including circulatory arrest in cardio-
vascular surgery.
Methods
Preparation of Hemagglutinating Virus of
Japan–Liposome Complexes
Hemagglutinating virus of Japan (HVJ)-liposome complexes were
prepared as described previously.11 In brief, phosphatidylserine,
phosphatidylcholine, and cholesterol were mixed in a weight ratio
of 1:4.8:2. The lipid mixture (10 mg) was deposited on the sides of
a flask by removing the solvent, tetrahydrofuran, in a rotary evap-
orator. The dried lipid was hydrated in 200 µL of a balanced salt
solution with 200 µg of ODNs. Liposomes were prepared by shak-
ing and sonication. The liposome suspension (0.5 mL containing
10 mg lipid) was mixed with inactivated HVJ (10,000 hemaggluti-
nating units) in a total volume of 4 mL of balanced salt solution.
The mixture was incubated at 4°C for 5 minutes and then for 30
minutes at 37°C with gentle shaking. Free HVJ was removed from
the HVJ-liposomes by means of sucrose density gradient centrifu-
gation. The top layer of the sucrose gradient was collected for use.
The sequences of the phosphorothioate ODNs were as follows:
NF-κB decoy ODNs, 5´-CCTTGAAGGGATTTCCCTCC-3´ and
3´-GGAACTTCCCTAAAGGGAGG-5´; scrambled decoy ODNs,
5´-TTGCCGTACCTGACTTAGCC-3´ and 3´-AACGGCATC-
CACTGAATCGG-5´.
Global Brain Ischemia Model
To establish the rat global brain ischemia-reperfusion model, we
modified the subclavian-carotid occlusion technique.13 Male
Sprague-Dawley rats weighing 300 to 350 g were used. All ani-
mals received humane care in compliance with the “Guide for the
Care and Use of Laboratory Animals” prepared by the Institute of
Laboratory Animal Resources in the Osaka University Medical
School. Each rat was anesthetized with 50 mg/kg pentobarbital
administered intraperitoneally and intubated into the mouth. The
rodent ventilator was set at 10 mL/kg volume and 50 to 60
strokes/min to maintain a PCO2 of 35 mm Hg. During the experi-
ment, rats were warmed on heating blankets at 36°C, except for the
brain. After thoracotomy, the left lobe of the thymus was removed.
The aortic arch was identified, and the innominate artery, left com-
mon carotid artery, and left subclavian artery were snared with 5-
0 nylon sutures. The right common carotid artery was exposed in
the neck and cannulated with a polyethylene tube (PE10, Becton
Dickinson Company, Franklin Lakes, NJ). Global brain ischemia
was induced by clamping all 3 sutured arteries for 20 minutes.
Immediately after the arteries were clamped, the HVJ-liposome
complex containing either the NF-κB decoy ODNs (NF decoy
group) or the scrambled decoy ODNs (S decoy group) was infused
into the right carotid artery to perfuse the brain tissue. These drugs
were stored at 4°C, and 2 mL per animal was infused. The pha-
ryngeal temperature fell from 35.2°C ± 0.2°C to 33.1°C ± 0.5°C
(mean ± standard deviation) in this procedure. No neurologic
events were observed in any animal after the surgical procedures.
The global ischemia-reperfusion brains were evaluated for 3
purposes. First, 3 rats were killed 1 hour after reperfusion, and
brain sections were observed with fluorescence microscopy to
investigate the transfection of fluorescein isothiocyanate
(FITC)–labeled ODN delivery. Second, 5 rats from each group
were killed 1 hour after reperfusion, and the hippocampus, includ-
ing the CA1 region, was collected to test the effect of transfected
NF-κB decoy ODNs on the expression of messenger RNAs that
are known to be activated by NF-κB. The samples weighed 20 to
25 mg after the blood vessels were stripped away. Third, 10 rats
from each group were killed 7 days after the global brain ischemia
for histologic study by means of terminal deoxynucleotidyl trans-
ferase–mediated dUTP nick end labeling (TUNEL) stain or
immunohistochemistry for microtubule-associated protein 2
(MAP2) to investigate the neuronal damage.
Quantification of TNF-α, IL-1β, and ICAM-1 mRNA
Levels in the Hippocampus
To clarify the effect of the in vivo transfection of the NF-κB decoy
ODNs versus the S decoy control ODNs on the expression of genes
that are known to respond to the signal of NF-κB 1 hour after
reperfusion, we used a real-time polymerase chain reaction (PCR)
system. This technique enables the quantification of complemen-
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tary DNA amplification and involves fluorescence-based real-time
PCR followed by measurement of the amplification with the ABI
PRISM 7700 Sequence Detection System (Applied Biosystems,
Foster City, Calif).
In brief, total RNA was purified from each 20- to 25-mg hip-
pocampus sample by using the RNAeasy Mini Kit, according to
the manufacturer’s instructions (Qiagen, Hilden, Germany). The
RNA samples were frozen in liquid nitrogen and stored at –80°C
until use. To test for gene transcription, 2 µg of RNA was reverse
transcribed with RNase-H–negative Moloney Mouse Leukemia
Virus reverse transcriptase (SUPERSCRIPT 2, Gibco BRL, Life
Technologies, Inc, Rockville, Md) in a total volume of 40 µL, as
recommended by the manufacturer. One eightieth of the cDNA
was used for each PCR reaction, and measurement of each tran-
script was performed in triplicate. The technique of real-time PCR
is based on the hydrolysis of a specific fluorescent probe at each
amplification cycle by the 5´-endonuclease activity of Taq poly-
merase. This technique was performed as described by Depre and
colleagues,14 with some modification. The nucleotide sequences of
the forward primers, reverse primers, and probes were as follows:
TNF-α, forward primer CCACCACGCTCTTCTGTCTACT,
reverse primer TTGGTGGTTTGCGACGACGT, and probe
CCCAGACCCTCACACTCAGATCATCTTC; IL-1β, forward
primer CCACCTCAATGGACAGAACATAAG, reverse primer
GACAAACCGCTTTTCCATCTTC, and probe CAAGGAGAGA-
CAAGCAACGACAAAATCCC; and ICAM-1, forward primer
TTCAAGCTGAGCGACATTGG, reverse primer TCAGTGTCT-
CATTCCCACGGA, and probe, TCTGCCACCATCACTGTG-
TATTCGTTCC.
For each molecule assayed here, the primer pair, or at least one
primer or probe, was designed to span one or more introns so that
only mRNA would be measured. In fact, when genomic DNA was
used as a target, no signal was detected for any of the molecules.
Primers and probes were used at 200 nmol/L in each PCR reaction,
and PCR was performed with 50 cycles of a 15-second denaturing
step at 95°C and a 1-minute annealing step at 60°C. The correla-
tion coefficient of the standard curves generated in each measure-
ment was always around 0.97 or better, and the coefficient of vari-
ance in the triplicate samples was usually less than 10%. Because
of the relative lack of precision in the measurement of RNA con-
centration with spectrophotometry, the level of transcripts for the
cellular enzyme glyceraldehyde 3-phosphate dehydrogenase
Figure 1. Transfection of rat tissue with FITC-labeled NF-κB decoy ODNs 1 hour after reperfusion. FITC fluores-
cence was observed entirely and could be observed in nuclei in neurons throughout the brain. A, Rat cortex sec-
tion; B, hippocampus. (Original magnification 40× [A-1, B-1] or 100× [A-2, B-2].)
A-1 A-2
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(GAPDH) was quantitatively measured in each sample as the inter-
nal control. The GAPDH primer and probe sequences were as fol-
lows: forward primer, CCATCACTGCCACTCAGAAGAC;
reverse primer, TCATACTTGGCAGGTTTCTCCA; and probe,
CGTGTTCCTACCCCCAATGTATCCGT.
The mRNA/GAPDH value was calculated for each sample, and
then the induction value compared with the normal rat
mRNA/GAPDH level was calculated.
TUNEL Staining and Immunohistochemistry
In normal animals 1 week after global brain ischemia, ischemic
damage can be detected, especially in the CA1 region of the hip-
pocampus, and the number of TUNEL-positive neurons increases.1
The presence of TUNEL-positive neurons does not directly reveal
the occurrence of apoptosis but does indicate DNA damage. The
expression levels of MAP2, a cytoskeletal protein, is a neuronal
marker of ischemic injury, and decreases in its expression have
been observed after global brain ischemia.15 To assess the effect of
transfecting the NF-κB decoy ODNs on neuronal ischemic injury,
brains were rapidly frozen in liquid nitrogen and sectioned coro-
nally through the rostrocaudal extent of the hippocampus. For
TUNEL staining, 5-µm sections were fixed in 1% paraformalde-
hyde. TUNEL staining was performed with the ApopTag In Situ
Apoptosis Detection Kit (Intergen Co, Purchase, NY), as recom-
mended by the manufacturer. The reaction product was visualized
by development with 3,3´-diaminobenzidine and H2O2. TUNEL-
stained brain sections were also stained with hematoxylin and
eosin. Then the percentage of the total number of neurons that
were TUNEL positive was calculated in the CA1 region (500 µm
in length) in 3 sections in each rat.
Immunohistochemistry was performed on the brain sections by
using the avidin-biotin peroxidase system (ABC kit; Vector
Laboratories, Inc, Burlingame, Calif). Five-micrometer sections
were fixed in 2% paraformaldehyde and incubated with a mono-
clonal MAP2 antibody (Upstate Biotechnology, Lake Placid, NY)
overnight at 4°C. Sections were stained by using the ABC
immunoperoxidase system, according to the manufacturer’s rec-
ommendations. The reaction product was visualized by develop-
Figure 2. Induction rate of mRNA in the rat hippocampus 1 hour after reperfusion. The levels of these mRNAs were
normalized to the mRNA levels of GAPDH in each sample, and the induction rates were calculated by comparing
them with levels in normal rat hippocampus. A, TNF-α mRNA; B, IL-1β mRNA; C, ICAM-1 mRNA. All values were
significantly suppressed in the NF-κB decoy group compared with in the S decoy group (P = .01).
A B
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ment with 3,3´-diaminobenzidine and H2O2, and these sections
were also stained with hematoxylin and eosin. Then the number of
MAP2-positive neurons was counted in the medial CA1 region
(500 µm in length) in 3 sections in each rat. 
Statistical Analysis
Data are presented as means ± standard deviation. Statistically sig-
nificant differences between the 2 groups were calculated with the
Mann-Whitney U test.
Results
In Vivo Transfection of NF-κB Decoy ODNs Through
the Carotid Artery During Global Brain Ischemia
In our preliminary study we infused the naked FITC-labeled
NF-κB ODNs into the carotid artery without any vector dur-
ing global brain ischemia. However, fluorescence was not
detected in the brain tissue by using this method (data not
shown). We next tried using the HVJ-liposome method to
transfect the NF-κB decoy ODNs into brain tissue. One
hour after reperfusion, in all of the rats examined, we
observed the transfection of cells with the FITC-labeled
ODNs not only in the intima of arteries but also in neurons,
especially those of the cortex and hippocampus (Figure 1).
The fluorescence was localized mainly to the cell nuclei.
Thus the NF-κB decoy ODNs could be transfected into the
brain tissue through the blood-brain barrier during global
brain ischemia in our model.
TNF-α, IL-1β, and ICAM-1 mRNA Expression in the
Hippocampus
In the NF decoy group the fold-induction rate of expression of
the gene encoding TNF-α 1 hour after reperfusion compared
with that seen in normal rats was 2.8 ± 1.1, whereas the fold
Figure 3. A, Sections through the rat hippocampus CA1 region with TUNEL stain 7 days after global brain ischemia.
NF-κB decoy ODN therapy (A-1) suppressed the appearance of TUNEL-positive neurons (stained in brown) com-
pared with in the S decoy group (A-2). B, Percentage of TUNEL-positive neurons in the hippocampus CA1 region
(500 µm in length). The percentage of TUNEL-positive neurons significantly decreased in the NF-κB decoy group
compared with in the S decoy group (P < .01). (Original magnification 100× [A-1, A-2].)
B
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induction was 12.5 ± 2.2 in the S decoy group. The fold-induc-
tion rates of IL-1β and ICAM-1 mRNA expression 1 hour
after reperfusion were 4.7 ± 1.7 and 3.5 ± 0.5 in the NF decoy
group and 14.0 ± 7.5 and 25.7 ± 12.0 in the S decoy group,
respectively (Figure 2). The expression of these 3 genes is acti-
vated by NF-κB and was effectively suppressed by the trans-
fection of NF-κB decoy ODNs through the carotid artery (P =
.01, P = .01, and P = .01, respectively). These data suggested
that the transfected NF-κB decoy ODNs effectively blocked
gene expression related to the NF-κB signal in ischemia-reper-
fusion injury in the hippocampus.
Blockade of Neuronal Damage by NF-κB Decoy ODNs
in the Hippocampus CA1 Region
Brain tissue was evaluated histologically 7 days after glob-
al brain ischemia to determine the protective effect of NF-
κB decoy ODNs against neuronal damage. TUNEL-positive
neurons were detected in both hemispheres, and the neu-
ronal damage was estimated in the right hemisphere.
In the NF decoy group, 7 days after global brain
ischemia, there were fewer TUNEL-positive neurons, com-
pared with in the S decoy group (11.3% ± 13.1% in the NF
decoy group and 40.3% ± 18.0% in the S decoy group, P =
.003; Figure 3). The number of MAP2-positive neurons was
higher in the NF decoy group than in the S decoy group
(96.4 ± 33.0 cells/500 µm length in the NF decoy group and
50.6 ± 23.8 cells/500 µm length in the S decoy group, P =
.005; Figure 4). These data show that transfecting NF-κB
decoy ODNs into neurons through the carotid artery attenu-
ated the neuronal damage after global brain ischemia.
Discussion
This study demonstrated evidence of attenuating neuronal
damage after global brain ischemia by using in vivo trans-
Figure 4. A, Sections of the rat hippocampus CA1 region with MAP2 immunohistologic stain 7 days after global brain
ischemia. NF-κB decoy ODNs therapy (A-1) suppressed the appearance of MAP2-negative neurons (without
immunoreactivity in the cytosol) compared with in the S decoy group (A-2). B, The number of MAP2-positive neurons
in the hippocampus CA1 region (500 µm in length). The number of MAP2-positive neurons was significantly maintained
in the NF decoy group compared with in the S decoy group (P < .01). (Original magnification 100× [A-1, A-2 ].)
B
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fection of a cis element decoy to bind the transcriptional
factor NF-κB. NF-κB decoy ODNs were successfully intro-
duced into the nuclei of neurons by infusing them through
the carotid artery and across the blood-brain barrier. The
transfected NF-κB decoy ODNs suppressed gene expres-
sion related to NF-κB signal in the hippocampus and atten-
uated neuronal damage caused by global brain ischemia, as
assessed by TUNEL labeling (DNA fragmentation) and the
immunoreactivity of MAP2 (neuronal marker). Thus, the
transfection of neurons with NF-κB decoy ODNs through
the carotid artery may provide a novel strategy to protect the
brain against ischemic injury during global brain ischemia.
Deep hypothermia is a basic strategy for brain protection
during circulatory arrest that reduces the cerebral energy
requirements. However, deep hypothermic circulatory arrest
carries an adverse risk of neurologic injury and is associat-
ed with complications, such as seizures, cerebral palsy,
motor dysfunction, and memory deficits.16-18 Neuronal
damage, including necrosis and delayed neuronal death, is
one cause of these neurologic injuries. In this study no neu-
rologic event was revealed in rats, and histologic study
showed no infarction area in the brain section. However, we
speculate that the rats 7 days after ischemia in the control
group may have had possibly impaired learning ability
compared with those in the NF-κB decoy group, although
all animals survived. Several methods in addition to deep
hypothermia have been reported to attenuate the neuronal
damage.19 However, these reports have mainly focused on
the regulation of energy requirements and metabolism, and
they have generally failed to prove the clinical success.
Therefore, alternative methods on the basis of other mecha-
nisms, such as the regulation of gene expression related to
ischemia-reperfusion injury, seem warranted.
Recent reports have demonstrated that apoptosis may
play an important role in delayed neuronal damage after cir-
culatory arrest.20,21 Many molecular signals, including the
inflammation-related cytokines and adhesion molecules, are
involved in apoptosis. These inflammation-related agents
are upregulated mainly by the transcriptional activation of
NF-κB, which is an oxidative-stress responsive signal. It is
unclear whether the regulation of cytokine mRNA levels,
such as TNF-α and IL-1β, directly blocks the neuronal
damage. However, at a minimum, these inflammatory
cytokines seem to contribute the ischemia-related neuronal
damage. Our data suggest that NF-κB may play an impor-
tant role in the attenuation of ischemia-reperfusion injury
and neuronal damage after global brain ischemia. TUNEL
staining is a nonspecific technique that may show DNA
injury and repair of DNA and may even be positive in
necrotic cells. Therefore, we are cautious to overstate apop-
tosis in TUNEL-positive neurons. However, histologic
examination showed that TUNEL-positive neurons were
about 15% in total neurons (fewer than TUNEL-positive
Cardiopulmonary Support and Physiology Ueno et al
neurons 7 days after global brain ischemia) 2 days after
global brain ischemia (data were not shown), and the neu-
ronal damage, including both necrosis and delayed neuronal
death, should occur at least between 2 days and 7 days after
global brain ischemia.
In addition, NF-κB has been speculated to work through
a number of pathways, and these might also induce neuronal
damage after global brain ischemia. These mechanisms are
as follows: (1) NF-κB activation may partially mediate free-
radical damage in several tissues, including the brain22; (2)
NF-κB activation seems to cause glutamate cytotoxicity9;
(3) NF-κB is likely to be instrumental in the upregulation of
inducible nitric oxide synthase and cyclooxygenase 223; and
(4) NF-κB may mediate the activation of the CD95 ligand,
which initiates delayed neuronal damage.24 These mecha-
nisms are all potential targets of the NF-κB decoy ODN
method. Moreover, target genes for NF-κB include the
apoptosis-related genes, including TP5325 and c-myc.26
Therefore, gene therapy with decoy ODNs against the NF-
κB binding site seemed a likely method to provide a new
strategy for neuronal protection during ischemia by sup-
pressing the gene expression related to the inflammatory
response and the subsequent neuronal damage, including
apoptosis.
Many investigators have reported strategies using gene
therapy for brain protection.27,28 In these reports genes were
injected into the subarachnoid space or brain ventricles.
However, no study has shown effective gene transfection by
means of injection through the carotid arteries because the
blood-brain barrier prevents the entry of many foreign sub-
stances and microorganisms. During and after global brain
ischemia, however, permeability across the blood-brain bar-
rier increases; in fact, relief of the blood-brain barrier has
been reported to extend for up to 6 hours after ischemia.29
We believe that our success in transfecting neurons with the
decoy ODNs was due to the accumulation of the HVJ-lipo-
some complex in the brain tissue. To the best of our knowl-
edge, this is the first report of successful gene transfection
through the carotid arteries and across the blood-brain bar-
rier. Further study is needed to clarify the mechanism of
gene transfer under these conditions.
Decoy therapy has many benefits, including immediate
effect, low cost, and few complications, and gene therapy
with naked E2F decoy has already been attempted in the
clinical setting to prevent vein graft disease.30 However,
transfection of naked ODNs has limitations in its efficiency
in the brain through the carotid artery in our preliminary
study. On the other hand, more safety vectors are in the
process of development. Therefore, clinical application of
NF-κB decoy therapy with HVJ-liposome or other vectors
through the carotid artery may be possibly attempted for
brain protection against ischemic injury during circulatory
arrest in the near future. NF-κB decoy ODN therapy
Ueno et al Cardiopulmonary Support and Physiology
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through vessels might have a potential of wide application
in clinical use for brain protection, such as retrograde per-
fusion of cerebroplegia.
In summary, the results of this study indicate that admin-
istration of NF-κB decoy ODNs during global brain
ischemia attenuates neuronal damage in the hippocampus
CA1 region in a rat model. Thus NF-κB decoy ODN admin-
istration through the carotid artery can protect neurons dur-
ing global brain circulatory arrest, raising the possibility
that NF-κB decoy ODNs may become a promising thera-
peutic agent for protecting the brain against global
ischemia. We believe that this method of gene transfection
to the brain might be applied not only in the field of cardiac
surgery but also in other fields, such as neurosurgery.
We thank Akiko Nishimura for production of the HVJ-lipo-
some complex and Shigeru Matsumi for animal care.
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